NCT00124527 2021-06-16
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Eisai Inc.
Phase 2 Completed
Clinical Trials
13 trialsNCT00053365 2019-07-24
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003441 2018-10-25
Irofulven in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003666 2016-07-20
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00003390 2013-06-21
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019552 2013-06-20
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005070 2013-06-19
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005968 2013-05-30
Irofulven in Treating Patients With Stage IV Melanoma
University of Colorado, Denver
Phase 2 Completed
NCT00005031 2013-05-27
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT00062257 2013-05-15
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003796 2013-02-11
Irofulven in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003760 2012-08-09
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed